A combination of silybin and carvedilol for treating liver fibrosis is more effective than either drug alone. | Drug ...

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.

November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective ...

The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.

The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. July 22, ...

NEW YORK Teva has settled a case against Dr. Reddy’s concerning its patent on carvedilol, the active ingredient in GlaxoSmithKline’s heart drug Coreg. Teva started filing suits last June to protect ...

Carvedilol could be the poster child for how to lower drug prices. Since 2007, over 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which ...

Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...

Please provide your email address to receive an email when new articles are posted on . A low-dose regimen of the blood pressure medication carvedilol demonstrated safety and efficacy in improving ...